{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:51:26Z","timestamp":1788868286137,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00296-019-04490-7","type":"journal-article","created":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T17:02:18Z","timestamp":1575738138000},"page":"169-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-3421","authenticated-orcid":false,"given":"Hazan","family":"Karadeniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-9797","authenticated-orcid":false,"given":"Asl\u0131han Avano\u011flu","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-4974","authenticated-orcid":false,"given":"Nuh","family":"Atas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7605-1301","authenticated-orcid":false,"given":"Hasan","family":"Sat\u0131\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0783-1072","authenticated-orcid":false,"given":"Reyhan Bilici","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-0259","authenticated-orcid":false,"given":"Hakan","family":"Babaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6244-9362","authenticated-orcid":false,"given":"Abdurrahman","family":"Tufan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,7]]},"reference":[{"key":"4490_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04412-7","author":"N Atas","year":"2019","unstructured":"Atas N, Armagan B, Bodakci E, Satis H, Sari A, Bilge NSY et al (2019) Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-019-04412-7","journal-title":"Rheumatol Int"},{"issue":"1","key":"4490_CR2","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1186\/ar4154","volume":"15","author":"S Akar","year":"2013","unstructured":"Akar S et al (2013) High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connection. Arthritis Res Ther 15(1):R21\u2013R21","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"4490_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","volume":"157","author":"PJ Hashkes","year":"2012","unstructured":"Hashkes PJ et al (2012) Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 157(8):533\u2013541","journal-title":"Ann Intern Med"},{"issue":"4Suppl26","key":"4490_CR4","first-page":"S45","volume":"20","author":"DL Gumucio","year":"2002","unstructured":"Gumucio DL et al (2002) Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol 20(4Suppl26):S45\u2013S53","journal-title":"Clin Exp Rheumatol"},{"issue":"16","key":"4490_CR5","doi-asserted-by":"publisher","first-page":"e3449","DOI":"10.1097\/MD.0000000000003449","volume":"95","author":"T Koga","year":"2016","unstructured":"Koga T et al (2016) Multiple serum cytokine profiling to identify combinational diagnostic biomarkers in attacks of familial Mediterranean fever. Medicine (Baltimore) 95(16):e3449\u2013e3449","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"4490_CR6","first-page":"88","volume":"42","author":"K Gok","year":"2017","unstructured":"Gok K et al (2017) Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever. Acta Reumatol Port 42(1):88\u201390","journal-title":"Acta Reumatol Port"},{"issue":"3","key":"4490_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/rheumatology\/key384","volume":"58","author":"JE Garcia-Robledo","year":"2019","unstructured":"Garcia-Robledo JE et al (2019) Tofacitinib for familial Mediterranean fever: a new alternative therapy? Rheumatology (Oxford) 58(3):553\u2013554","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4490_CR8","first-page":"721","volume":"16","author":"S Kiraz","year":"1998","unstructured":"Kiraz S et al (1998) Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 16(6):721\u2013724","journal-title":"Clin Exp Rheumatol"},{"key":"4490_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM et al (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41","journal-title":"J Inflamm (Lond)"},{"issue":"6","key":"4490_CR10","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/art.34329","volume":"64","author":"K Maeshima","year":"2012","unstructured":"Maeshima K et al (2012) The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 64(6):1790\u20131798","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4490_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/rheumatology\/key070","volume":"58","author":"DJ Veale","year":"2019","unstructured":"Veale DJ et al (2019) The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford) 58(2):197\u2013205","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04490-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04490-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04490-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:41:52Z","timestamp":1607215312000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04490-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,7]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["4490"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04490-7","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,7]]},"assertion":[{"value":"22 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AT is Consultant for: Novartis and Abdi Ibrahim, Speaker Bureau of: Novartis, Pfizer and UCB with no conflict related to this study. AT is editorial board member of two international journals and reviewer for 3 international journals and research funding bodies. None of the authors have conflict of interest and non-financial relationships with agencies promoting tofacitinib.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of \u0131nterest"}},{"value":"Written informed consent was obtained from all subjects. Permissions was taken from regulatory agencies for off-label uses of drugs. For each patient, we applied for permission of use and shared our Patient files with Medical Devices Agency of the Turkish Ministry of Health. The Turkish Ministry of Health granted the compassionate use of tofacitinib for FMF patients with special permission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}